Aigul Erbosynovna Malmakova

Dr. Aigul Erbosynovna Malmakova

Aigul Malmakova earned her Bachelor’s (2005) and Master’s (2...

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 June 2024 in Molecules
Verified
Journal Article
Open access
PDF file
RARidho Asra
Ridho Asra
AMAigul Erbosynovna Malmakova
Aigul Erbosynovna Malmakova
Alan JonesAlan Jones
Alan Jones
The tractable preparation of Phase I drug metabolites is a critical step to understand the first-pass behaviour of novel chemical entities (NCEs) in drug discovery. In this study, we have developed a structure–electroactivity relationship (SeAR)-informed electrochemical reaction of the parent 2-chlorophenothiazine and the antipsychotic medication, chlorpromazine. With the ability to dial-in under current controlled conditions, the formation of S-oxide and novel S,S-dioxide metabolites has been achieved for the first time on a multi-milligram scale using a direct batch electrode platform. A potential rationale for the electrochemical formation of these metabolites in situ is proposed using molecular docking to a cytochrome P450 enzyme.

16 June 2022 in Molecules
Verified
Journal Article
Open access
PDF file
ENEkaterina Neborak
Ekaterina Neborak
Altynay KaldybayevaAltynay Kaldybayeva
Altynay Kaldybayeva
LBLylia Bey
Lylia Bey
AMAigul Erbosynovna Malmakova
Aigul Erbosynovna Malmakova
ATAnna S. Tveritinova
Anna S. Tveritinova
DZDmitry D. Zhdanov
Dmitry D. Zhdanov
Polyamine (PA) catabolism is often reduced in cancer cells. The activation of this metabolic pathway produces cytotoxic substances that might cause apoptosis in cancer cells. Chemical compounds able to restore the level of PA catabolism in tumors could become potential antineoplastic agents. The search for activators of PA catabolism among bicyclononan-9-ones is a promising strategy for drug development. The aim of the study was to evaluate the biological activity of new 3,7-diazabicyclo[3.3.1]nonan-9-one derivatives that have antiproliferative properties by accelerating PA catabolism. Eight bispidine derivatives were synthetized and demonstrated the ability to activate PA catabolism in regenerating rat liver homogenates. However, only three of them demonstrated a potent ability to decrease the viability of cancer cells in the MTT assay. Compounds 4c and 4e could induce apoptosis more effectively in cancer HepG2 cells rather than in normal WI-38 fibroblasts. The lead compound 4e could significantly enhance cancer cell death, but not the death of normal cells if PAs were added to the cell culture media. Thus, the bispidine derivative 4e 3-(3-methoxypropyl)-7-[3-(1H-piperazin-1-yl)ethyl]-3,7-diazabicyclo[3.3.1]nonane could become a potential anticancer drug substance whose mechanism relies on the induction of PA catabolism in cancer cells.

10 October 2025 in Organics
Verified
Journal Article
Open access
PDF file
AMAigul Erbosynovna Malmakova
Aigul Erbosynovna Malmakova
Alan JonesAlan Jones
Alan Jones
This review offers a focused overview of the strategies used to build and modify phenothiazine (PTZ) derivatives. It covers both classical synthetic approaches and advances reported since 2014, including transition metal-catalyzed transformations and greener techniques, such as electrosynthesis, microwave-assisted reactions, and ultrasound-promoted methods. Each strategy is evaluated with respect to efficiency, scalability, and sustainability. In parallel, the review surveys the diverse bioactivity profiles of PTZ derivatives, ranging from antipsychotic, anticancer, and antimicrobial activities to emerging applications in photodynamic therapy and neuroprotection. By correlating synthetic accessibility with biological potential, this review provides an integrated perspective that highlights advances achieved since 2014 and outlines future opportunities for rational PTZ design and applications.

12 August 2025 in ChemRxiv
Verified
Preprint
Open access
PDF file
AMAigul Erbosynovna Malmakova
Aigul Erbosynovna Malmakova
Alan JonesAlan Jones
Alan Jones
This review focuses on the synthesis of phenothiazine derivatives employing novel synthetic strategies, including non-metallic reagent-promoted, transition metal-catalysed, and related green chemistry approaches. The therapeutic characteristics of the phenothiazine class are highlighted including antibiotic, antitubercular, antidiabetic, antagonistic, antioxidant, anti-obesity, plas-mid-curing activities, and in cancer therapy. Decorated phenothiazine scaffolds demonstrated di-verse mechanisms of action including activation of proteasomes, inhibition of the cleavage of bac-terial RPR, against various strains of yeast and filamentous fungi, oxidative stress, efficacy of treatments against resistant bacterial strains, selection of binding affinity to CB1R and histone deacetylase 6, reduction of cell growth, inhibition of tumour cell proliferation, human farnesyl-transferase, induction of apoptosis, necrosis, arrest of cell cycle at G0/G1 phase, and modulation of immune responses amongst many others. Through their synergistic effects with antibiotics, the study demonstrated the promise of phenothiazines in treating multidrug-resistant tuberculosis, offering a different therapeutic approach to managing this difficult to treat disease. Phenothiazine derivatives have demonstrated potential as an adjunct for improving the effectiveness of traditional chemotherapy and disrupting the signalling pathways of microorganisms and cancer cells.

25 June 2025 in Molecules
Verified
Journal Article
Open access
PDF file
VYValentina Konstantinovna Yu
Valentina Konstantinovna Yu
MBMarina Balabekova
Marina Balabekova
ATAssel Yurevna Ten
Assel Yurevna Ten
TZTolganay Zharkynbek
Tolganay Zharkynbek
Sulev KoksSulev Koks
Sulev Koks
KTKhaidar Tassibekov
Khaidar Tassibekov
Acute pneumonia is frequently accompanied by immune suppression, particularly affecting T-cell subsets, such as CD4+, CD4+CD25+, and CD4+CD25+FoxP3+, which are critical for immune regulation. This study evaluates the immunomodulatory potential of a novel fluorinated piperazine-based aminophosphonate, complexed with β-cyclodextrin ((o-Fph)PPhβCD), comparing it with the clinically approved agent Polyoxidonium (PO) in a rat model of oleic acid-induced acute pneumonia. Flow cytometric analysis revealed that (o-Fph)PPhβCD significantly restored CD4+ and CD4+CD25+ T-cell levels and induced a sustained reduction in regulatory CD4+CD25+FoxP3+ cells, suggesting enhanced effector immune activity. While PO provided early immunorestorative effects, (o-Fph)PPhβCD exerted a more prolonged response, which was particularly evident by day 14. Structural confirmation of the inclusion complex was achieved through IR and NMR spectroscopy. These findings highlight (o-Fph)PPhβCD as a promising immunotherapeutic candidate that is capable of rebalancing immune cell populations and supporting host defense mechanisms during acute pulmonary inflammation.

8 March 2021 in Pharmaceutical Chemistry Journal
Verified
Journal Article
Closed access
PDF file
SZS. S. Zhumakova
S. S. Zhumakova
AMAigul Erbosynovna Malmakova
Aigul Erbosynovna Malmakova
VYV. K. Yu
V. K. Yu
KPK. D. Praliev
K. D. Praliev
TIT. K. Iskakova
T. K. Iskakova
TST. M. Seilkhanov
T. M. Seilkhanov